| Powder: | Yes |
|---|---|
| Customized: | Non-Customized |
| Certification: | Coa, MSDS |
| Suitable for: | Other |
| State: | Powder |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier
| {Product Name}: | Entecavir |
| {Other Name}: | N/A |
| {Test Method.}: | HPLC |
| {Appearence.}: | White Powder |
| {Specification}: | 99% |
| {MOQ}: | 1kg |
Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. Entecavir is a nucleoside analog (more specifically, a guanosineanalogue) that inhibits reverse transcription, DNA replication and transcription in the viral replication process. It also helps prevent the hepatitis B virus from multiplying and infecting new liver cells. Entecavir is also indicated for the treatment of chronic hepatitis B in adults with HIV/AIDS infection.
Function of Treatment Hepatitis B Anti-HBV Drugs Raw Material Medicine Grade CAS 142217-69-4 Bulk 99% Entecavir Powder
Entecavir is an oral drug for the treatment of hepatitis B virus infection of a new generation of guanine nucleoside analogues, mainly for the treatment of adults with active viral replication and serum transaminase activity continued to increase, as lesions of chronic hepatitis B or liver tissue, is currently the fastest and strongest drop virus mutation rate lowest nucleoside analogues.
The data show that different in patients with chronic hepatitis B, including nucleoside naive, nucleoside treated and cirrhotic patients, through the use of entecavir therapy can rapidly control the disease, easily reach treatment end point that hepatitis B virus is not realistic, measurable; through adherence to treatment, a considerable part of the patients can reach satisfactory treatment end point, i.e. e antigen seroconversion, some patients even can reach the ideal end point of treatment, namely surface antigen negative.
This product is a nucleoside analogue of guanine, which has inhibitory effect on hepatitis B virus (HBV) polymerase. It can be converted into active three phosphate by phosphorylation, and the half-life of three phosphate in cells is 15 hours. The natural substrate and HBV polymerase three phosphate deoxyguanosine competition, entecavir three phosphate can inhibit the viral polymerase (reverse transcriptase) of all three activities: (1) HBV polymerase promoter; (2) before the formation of genomic mRNA reverse transcription negative strand synthesis; (3) HBV DNA is the chain. The inhibitory constant (Ki) of entecavir three phosphate against HBV DNA polymerase was 0.0012 mu M. Entecavir three phosphate inhibited the alpha, beta, Delta DNA polymerase, and mitochondrial gamma DNA polymerase of cells less, and the Ki value was 18, as far as 160 M.
Send us an inquiry
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}